With respect to the analysis of EZH2 expression in CRC, the use of various scoring systems, different cutoff values, or mixed patient cohorts of colon and rectal tumors make it very difficult to compare the different studies and question the clinical application of EZH2 as a reliable biomarker. This evidence concerns the gene EZH2 and rectal neoplasm.